Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024
February 02, 2024 at 04:38 pm EST
Share
On January 29, 2024, Ching W. Jaw, Senior Vice President & Chief Financial Officer, informed Cytokinetics, Incorporated (the "Company") that he would be resigning his office and employment with the Company effective February 23, 2024. Mr. Jaw's stated reason for departure is to attend to a personal health condition and his departure is on mutually good terms between the Company and himself.
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
CYTOKINETICS, INCORPORATED 
